Drug Profile


Alternative Names: Human IgE pentapeptide; Pentyde

Latest Information Update: 28 Jul 1994

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Dura Pharmaceuticals
  • Developer Bausch & Lomb; Carlbiotech; Dura Pharmaceuticals; Tanabe Seiyaku
  • Class Antiallergics; Immunoglobulin isotypes; Peptide fragments; Small molecules
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Allergic conjunctivitis; Allergic rhinitis; Asthma

Most Recent Events

  • 29 Jul 1993 Discontinued-Clinical for Allergic conjunctivitis in USA (Ophthalmic)
  • 29 Jul 1993 Discontinued-Clinical for Allergic rhinitis in USA (Intranasal)
  • 29 Jul 1993 Discontinued-I for Allergic rhinitis in Japan (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top